Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Protocol for ZEN003694 in mCRPC
NCT04145375Phase 2Enrolling by invitation
- Sponsor
- Zenith Epigenetics
- Start
- Nov 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZEN3694 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zenith Epigenetics. Started Nov 2019; status: enrolling by invitation.
02
Drugs
ZEN3694
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04145375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145375.